Non-small lung cancer. Expanding therapeutic opportunities: pembrolizumab in a number of malignant tumors
- Autores: Gutorov S.L1, Borisova E.I1, Abramov M.E1, Lud A.N1, Arutyunyan E.A1
-
Afiliações:
- FSBI “Russian Oncological Research Center n.a. N.N. Blokhin" RAMS
- Edição: Nº 8 (2017)
- Páginas: 71-75
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289857
- ID: 289857
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The article presents results of studies of the use of pembolizumab in a number of malignant tumors. Pembolizumab belongs to a fundamentally new class of antitumor agents, PD-1/PD-L1 control point inhibitors, whose therapeutic effect is achieved by reactivation of antitumor immune effect.
Palavras-chave
Texto integral
Sobre autores
S. Gutorov
FSBI “Russian Oncological Research Center n.a. N.N. Blokhin" RAMS
E. Borisova
FSBI “Russian Oncological Research Center n.a. N.N. Blokhin" RAMS
M. Abramov
FSBI “Russian Oncological Research Center n.a. N.N. Blokhin" RAMS
A. Lud
FSBI “Russian Oncological Research Center n.a. N.N. Blokhin" RAMS
Email: hanna_lud@msn.com
Department of Chemotherapy and Combined Treatment of Malignant Tumors
E. Arutyunyan
FSBI “Russian Oncological Research Center n.a. N.N. Blokhin" RAMS
Bibliografia
- Garon E.B., Rizvi N.A., Hui R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015;372:2018-28.
- Herbst R.S., Baas P., Kim D.W., Felip E., Prez-Gracia J.L., Han J.Y., Molina J., Kim J.H., Arvis C.D., Ahn M.J., Majem M., Fidler M.J., de Castro G. Jr, Garrido M., Lubiniecki G.M., Shentu Y., Im E., Dolled-Filhart M., Garon E.B. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non- small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-50.
- Hellman M.D., Garon E.B., Gandhi L., et al. Efficacy of Pembrolizumab in Key Subgroups of Patients with Advanced NSCLC. WCLC. 2015;(Abstr.3057).
- Baas R., Garon E.B., Herbst R.S., et al. Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1-Positive NSCLC. J Clin Oncol. 2016;34. Abstr. 9015.
- Reck M., Rodrlguez-Abreu D., Robinson A.G., Hui R., Csoszi T., Fülöp A., Gottfried M., Peled N., Tafreshi A., Cuffe S., O'Brien M1, Rao S., Hotta K., Leiby M.A., Lubiniecki G.M., Shentu Y., Rangwala R., Brahmer J.R. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2016;375(19):1823.
- Robert C., Ribas A., Hamid O., et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J. Clin. Oncol. 2016;34(Suppl., abstr. 9503).
- Ribas A., Hamid O., Daud A., et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016;315:1600-609.
- Robert C. New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at ASCO. Ann. Meeting, 2016;(Abstr. 9503).
- Puzanov I., Dummer R., Schachter J., et al. Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory advanced melanoma. J. Clin. Oncol. 2015;33(Suppl., abstr. 3012).
- Daud A., Blank C., Robert C., Puzanov I., et al., KEYNOTE-006 study of pembrolizumab versus ipilimumab for advanced melanoma: Efficacy by PD-L1 expression and line of therapy. J. Clin. Oncol. 2016;34(Suppl., abstr. 9513).
- Schachter J. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. ASCO. Ann. Meeting. 2016;(Abstr. 9504).
- Butler M., Hamid O., Ribas A., et al. Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies. Eur. J. Cancer. 2017;72(Suppl. 1):123.
Arquivos suplementares
